HTG Molecular Diagnostics (HTG Molecular Diagnostics) Momentum Rank : 0 (As of May. 17, 2024)

View and export this data going back to 2015. Start your Free Trial

What is HTG Molecular Diagnostics Momentum Rank?

HTG Molecular Diagnostics has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

HTG Molecular Diagnostics Momentum Rank Related Terms

Thank you for viewing the detailed overview of HTG Molecular Diagnostics's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

HTG Molecular Diagnostics (HTG Molecular Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » HTG Molecular Diagnostics Inc (OTCPK:HTGMQ) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

3430 E. Global Loop, Tucson, AZ, USA, 85706

Website

https://www.htgmolecular.com

HTG Molecular Diagnostics Inc is a commercial-stage RNA platform-based life sciences company focused on advancing the promise of precision medicine. Its proprietary NGS-adapted chemistry and HTG EdgeSeq platform automates sample processing and can quickly, robustly, and simultaneously profile hundreds or thousands of molecular targets using a relatively small amount of biological samples, in liquid or solid forms. Its products include instruments, consumables, and software that combine to form its HTG EdgeSeq platform. The company's menu of HTG EdgeSeq molecular profiling panels is automated on its HTG EdgeSeq platform, applying genomic sequencing tools to quickly generate gene expression data using its simplified workflow for customers.

Executives

Stephen Barat	officer: Senior VP of Therapeutics	C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Thomas W. Dubensky	director	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
L5 Capital Inc.	10 percent owner	1 FIRST CANADIAN PLACE, 39TH FLOOR, TORONTO A6 M5X 1H3
Christopher P Kiritsy	director
Byron Lawson	officer: SVP/Chief Commercial Officer	C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Tim B Johnson	director, officer: President & CEO
Laurence W Lytton	10 percent owner	467 CENTRAL PARK WEST, NY NY 10025
Laura Lee Godlewski	officer: VP of Accounting and Reporting	C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Michelle Renee Griffin	director	19723 NE 65TH LANE, KIRKLAND WA 98033
Shaun D Mcmeans	officer: VP, Finance & Admin. & CFO	3708 E COLUMBIA STREET, SUITE #110, TUCSON AZ 85714-3413
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Plc Glaxosmithkline	10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Nv Qiagen	10 percent owner	HULSTERWEG 82, PL VENLO P7 5912
Ann Hanham	director	ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111
Don M Hardison	director